Medline Inc.
NASDAQ:MDLN · NASDAQ Global Select
-$0.42 today
Vol 13.95M · Avg 9.27M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
10.8%
avg 4.9%
ROIC
5.7%
avg 3.9%
ROA
3.0%
avg 1.7%
Analysis
ROE is currently the strongest return metric at 10.8% versus its period average of 4.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
James Boyle | CEO & Director | $2.68M | — | 54 | — | — |
Michael Drazin | Chief Financial Officer | $1.60M | — | 51 | — | — |
Douglas Golwas | Chief Commercial Officer | $1.60M | — | 57 | — | — |
Stephen L. Miller | Chief Operating Officer | $1.49M | — | 55 | — | — |
Alex Liberman | Chief Legal Officer | — | — | 61 | — | — |
Ben Fox | Vice President of Corporate Communications | — | — | — | — | — |
Marshall Lancaster | Chief Information Officer | — | — | — | — | — |
Jessi L. Corcoran | Chief Accounting Officer | — | — | 43 | — | — |
Karen King | Global Head Investor Relations | — | — | — | — | — |
Jenny Lee | Chief Marketing Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
12
$4.35B
Net Sentiment
$4.35B
Net selling
Most Active
BCP 8 Holdings Mozart Manager L.L.C.
8 transactions
1–10 of 12
Analysis
Insiders reported 0 buys worth $0.00 and 12 sells worth $4.35B over the last 12 months. That adds up to net selling of $4.35B. BCP 8 Holdings Mozart Manager L.L.C. was the most active insider with 8 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +10.8% (5yr)3 analysts |
| Revenue | N/A | N/A | +9.9% | +7.8% (5yr)9 analysts |
| Net Income | N/A | N/A | N/A | +10.8% (5yr)9 analysts |
| EBIT | N/A | N/A | +36.5% | +3.7% (5yr)9 analysts |
Analysis
Recent growth has been strongest in EBIT at +36.5% over three years. Forward estimates point to Net Income at +10.8% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
ResMed Inc.
NYSE:RMD
$27.26B
The Cooper Companies, Inc.
NASDAQ:COO
$12.85B
Avantor, Inc.
NYSE:AVTR
$6.54B
Bausch + Lomb Corporation
NYSE:BLCO
$5.32B
Netskope, Inc. Class A Common Stock
NASDAQ:NTSK
$3.61B
LeMaitre Vascular, Inc.
NASDAQ:LMAT
$2.13B
Kestra Medical Technologies, Ltd.
NASDAQ:KMTS
$1.17B
Lumexa Imaging Holdings, Inc. Common Stock
LMRI
$887.79M
InfuSystem Holdings, Inc.
AMEX:INFU
$186.28M
Black Rock Coffee Bar, Inc. Class A Common Stock
NASDAQ:BRCB
$136.95M
Who manages MDLN?
Medline Inc. (MDLN) lists 10 active executives. The top listed executive is Alex Liberman, Chief Legal Officer.
Are MDLN insiders buying or selling?
Recent insider activity shows net selling of $4.35B.
Explore More
Continue the stock analysis
Jump to another research area for this company.